Bruce C V Campbell Selected Research

Tenecteplase

1/2022	Safety and Efficacy of Tenecteplase in Older Patients With Large Vessel Occlusion: A Pooled Analysis of the EXTEND-IA TNK Trials.
1/2022	Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.
1/2022	Reduced Severity of Tissue Injury Within the Infarct May Partially Mediate the Benefit of Reperfusion in Ischemic Stroke.
1/2022	Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design.
1/2022	Thrombectomy versus Medical Management in Mild Strokes due to Large Vessel Occlusion: Exploratory Analysis from the EXTEND-IA Trials and a Pooled International Cohort.
1/2021	Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.
1/2021	Tenecteplase Thrombolysis in Posterior Circulation Stroke.
1/2021	Tenecteplase vs Alteplase Before Endovascular Therapy in Basilar Artery Occlusion.
12/2020	Cost-Effectiveness of Tenecteplase Before Thrombectomy for Ischemic Stroke.
1/2020	Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bruce C V Campbell Research Topics

Disease

82	Stroke (Strokes) 02/2022 - 01/2010
77	Ischemic Stroke 02/2022 - 01/2010
16	Infarction (Infarctions) 01/2022 - 06/2011
8	Hemorrhage 01/2022 - 01/2010
6	Hematoma 01/2022 - 11/2013
4	Brain Edema (Cerebral Edema) 01/2022 - 01/2016
4	Cerebral Infarction 11/2020 - 07/2017
3	Arterial Occlusive Diseases (Arterial Occlusive Disease) 01/2022 - 01/2014
3	Cerebral Hemorrhage 01/2022 - 06/2014
3	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2021 - 07/2016
3	Atrial Fibrillation 11/2020 - 10/2019
2	Edema (Dropsy) 01/2022 - 11/2021
2	Body Weight (Weight, Body) 01/2018 - 03/2015
2	Lacunar Stroke 07/2016 - 06/2013
1	Brain Ischemia (Cerebral Ischemia) 01/2022
1	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2022
1	Paralysis (Palsy) 02/2021
1	Angioedema 01/2021
1	Wounds and Injuries (Trauma) 12/2020
1	Patent Foramen Ovale 11/2020
1	Carotid Stenosis (Carotid Artery Stenosis) 10/2019
1	Thrombosis (Thrombus) 05/2019
1	Neurologic Manifestations (Neurological Manifestations) 01/2019
1	Hyperglycemia 01/2019
1	Seizures (Absence Seizure) 05/2018
1	Epilepsy (Aura) 05/2018
1	Pathologic Constriction (Stenosis) 01/2017
1	Traumatic Brain Injuries (Traumatic Brain Injury) 03/2016
1	Atrophy 01/2016
1	Kidney Diseases (Kidney Disease) 06/2013
1	Parkinson Disease (Parkinson's Disease) 08/2002

Drug/Important Bio-Agent (IBA)

42	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2022 - 01/2010
15	Tenecteplase FDA Link 01/2022 - 01/2017
9	Cytidine Triphosphate (CTP)IBA 01/2022 - 12/2011
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 06/2014
3	Tranexamic Acid (AMCA)FDA Link 01/2022 - 06/2014
3	Glucose (Dextrose)FDA LinkGeneric 11/2021 - 12/2014
2	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2022 - 01/2022
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 06/2015
2	Indicators and Reagents (Reagents)IBA 12/2018 - 11/2018
1	Amyloid (Amyloid Fibrils)IBA 01/2022
1	GadoliniumIBA 01/2022
1	SolutionsIBA 08/2021
1	Neuroprotective AgentsIBA 01/2020
1	idarucizumabIBA 01/2020
1	Dabigatran FDA Link 01/2020
1	antineoplaston A10 (A 10)IBA 01/2020
1	CholesterolIBA 10/2019
1	ORALIT (ORS)IBA 07/2017
1	CreatineIBA 01/2016
1	Inositol (Myoinositol)IBA 01/2016
1	N-acetylaspartate (N-acetyl aspartate)IBA 01/2016
1	IceIBA 01/2016
1	Biological ProductsIBA 06/2015
1	RivaroxabanIBA 11/2014
1	Factor Xa (Coagulation Factor Xa)IBA 11/2014
1	Uric Acid (Urate)IBA 05/2014
1	2,6-dinitrotoluene (DNT)IBA 09/2013
1	Aligeron (AS 2)IBA 06/2013
1	alpha-SynucleinIBA 08/2002
1	SynucleinsIBA 08/2002

Therapy/Procedure

51	Therapeutics 02/2022 - 01/2010
46	Thrombectomy 02/2022 - 03/2015
9	Stents 02/2021 - 03/2015
3	Aftercare (After-Treatment) 01/2019 - 07/2013
2	Punctures 01/2022 - 01/2019
2	Secondary Prevention 01/2021 - 10/2019
2	Carotid Endarterectomy 11/2020 - 10/2019
1	Conservative Treatment 02/2022
1	Neurosurgical Procedures 01/2022
1	Brain-Computer Interfaces 02/2021
1	Activities of Daily Living (ADL) 02/2021
1	Electrodes (Electrode) 02/2021
1	Patient Admission (Patient Admissions) 01/2021
1	Subacute Care 12/2020
1	Patient Readmission 12/2020
1	Time-to-Treatment 05/2019
1	Intravenous Infusions 01/2018
1	Craniotomy 03/2016
1	Treatment Delay 08/2015
1	Stretchers 09/2013
1	Thrombolytic Therapy 01/2012